"Adjuvants, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
| Descriptor ID |
D000276
|
| MeSH Number(s) |
D27.505.696.477.067
|
| Concept/Terms |
Adjuvants, Immunologic- Adjuvants, Immunologic
- Immunostimulants
- Adjuvant, Immunologic
- Immunologic Adjuvant
- Immunological Adjuvant
- Adjuvant, Immunological
- Immunoactivators
- Immunoadjuvants
- Immunologic Adjuvants
- Immunopotentiators
- Adjuvants, Immunological
- Immunological Adjuvants
|
Below are MeSH descriptors whose meaning is more general than "Adjuvants, Immunologic".
Below are MeSH descriptors whose meaning is more specific than "Adjuvants, Immunologic".
This graph shows the total number of publications written about "Adjuvants, Immunologic" by people in this website by year, and whether "Adjuvants, Immunologic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 3 | 2 | 5 |
| 2004 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 1 | 3 |
| 2009 | 1 | 1 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 4 | 4 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adjuvants, Immunologic" by people in Profiles.
-
Sutherland L, Laschinger M, Syed ZU, Gaspari A. Treatment of alopecia areata with topical sensitizers. Dermatitis. 2015 Jan-Feb; 26(1):26-31.
-
Khong A, Cleaver AL, Fahmi Alatas M, Wylie BC, Connor T, Fisher SA, Broomfield S, Lesterhuis WJ, Currie AJ, Lake RA, Robinson BW. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40. BMC Cancer. 2014 Dec 17; 14:969.
-
Hamamoto S, Okuma T, Yamamoto A, Kageyama K, Ueki A, Matsuoka T, Miki Y. Combination radiofrequency ablation and local injection of the immunostimulant bacillus Calmette-Guérin induces antitumor immunity in the lung and at a distant VX2 tumor in a rabbit model. J Vasc Interv Radiol. 2015 Feb; 26(2):271-8.
-
Tao Y, Zhang X, Chopra M, Kim MJ, Buch KR, Kong D, Jin J, Tang Y, Zhu H, Jewells V, Markovic-Plese S. The role of endogenous IFN-ß in the regulation of Th17 responses in patients with relapsing-remitting multiple sclerosis. J Immunol. 2014 Jun 15; 192(12):5610-7.
-
Chahdi A, Raufman JP. The Cdc42/Rac nucleotide exchange factor protein ß1Pix (Pak-interacting exchange factor) modulates ß-catenin transcriptional activity in colon cancer cells: evidence for direct interaction of ß1PIX with ß-catenin. J Biol Chem. 2013 Nov 22; 288(47):34019-29.
-
Lee CG, Herzog EL, Ahangari F, Zhou Y, Gulati M, Lee CM, Peng X, Feghali-Bostwick C, Jimenez SA, Varga J, Elias JA. Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-ß1 signaling. J Immunol. 2012 Sep 1; 189(5):2635-44.
-
Wanjalla CN, Goldstein EF, Wirblich C, Schnell MJ. A role for granulocyte-macrophage colony-stimulating factor in the regulation of CD8(+) T cell responses to rabies virus. Virology. 2012 May 10; 426(2):120-33.
-
Abraham D, Hess JA, Mejia R, Nolan TJ, Lok JB, Lustigman S, Nutman TB. Immunization with the recombinant antigen Ss-IR induces protective immunity to infection with Strongyloides stercoralis in mice. Vaccine. 2011 Oct 19; 29(45):8134-40.
-
McKiernan JM, Barlow LJ, Laudano MA, Mann MJ, Petrylak DP, Benson MC. A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guérin refractory nonmuscle invasive bladder cancer. J Urol. 2011 Aug; 186(2):448-51.
-
Mahipal A, Terai M, Berd D, Chervoneva I, Patel K, Mastrangelo MJ, Sato T. Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol Immunother. 2011 Jul; 60(7):1039-45.